Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study. by Poirot, Eugenie et al.
UCSF
UC San Francisco Previously Published Works
Title
Development of a pharmacovigilance safety monitoring tool for the rollout of single low-
dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections 
in Swaziland: a pilot study.
Permalink
https://escholarship.org/uc/item/40f2b6p3
Journal
Malaria journal, 15(1)
ISSN
1475-2875
Authors
Poirot, Eugenie
Soble, Adam
Ntshalintshali, Nyasatu
et al.
Publication Date
2016-07-22
DOI
10.1186/s12936-016-1410-7
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Poirot et al. Malar J  (2016) 15:384 
DOI 10.1186/s12936-016-1410-7
RESEARCH
Development of a pharmacovigilance 
safety monitoring tool for the rollout 
of single low-dose primaquine 
and artemether-lumefantrine to treat 
Plasmodium falciparum infections in Swaziland: 
a pilot study
Eugenie Poirot1,2* , Adam Soble3, Nyasatu Ntshalintshali3, Asen Mwandemele4, Nomcebo Mkhonta5, 
Calisile Malambe5, Sibonakaliso Vilakati5, Sisi Pan3, Sarah Darteh6, Gugu Maphalala7, Joelle Brown1,2, 
Jimee Hwang1,8, Cheryl Pace9, Andy Stergachis10, Eric Vittinghoff2, Simon Kunene5 and Roland Gosling1,2
Abstract 
Background: Countries remain reluctant to adopt the 2012 World Health Organization recommendation for single 
low-dose (0.25 mg/kg) primaquine (SLD PQ) for Plasmodium falciparum transmission-blocking due to concerns over 
drug-related haemolysis risk, especially among glucose-6-phosphate dehydrogenase-deficient (G6PDd) people, 
without evidence demonstrating that it can be safely deployed in their settings. Pharmacovigilance methods provide 
a systematic way of collecting safety data and supporting the rollout of SLD PQ.
Methods: The Primaquine Roll Out Monitoring Pharmacovigilance Tool (PROMPT), comprising: (1) a standardized 
form to support the surveillance of possible adverse events following SLD PQ treatment; (2) a patient information 
card to enhance awareness of known adverse drug reactions of SLD PQ use; and (3) a database compiling recorded 
information, was developed and piloted. Data on patient characteristics, malaria diagnosis and treatment are col-
lected. Blood samples are taken to measure haemoglobin (Hb) and test for G6PD deficiency. Active follow-up includes 
a repeat Hb measurement and adverse event monitoring on or near day 7. A 13-month prospective pilot study in two 
hospital facilities in Swaziland alongside the introduction of SLD PQ generated preliminary evidence on the feasibility 
and acceptability of PROMPT.
Results: PROMPT was well received by nurses as a simple, pragmatic approach to active surveillance of SLD PQ safety 
data. Of the 102 patients enrolled and administered SLD PQ, none were G6PDd. 93 (91.2 %) returned on or near day 7 
for follow-up. Four (4.6 %) patients had falls in Hb ≥25 % from baseline, none of whom presented with signs or symp-
toms of anaemia. No patient’s Hb fell below 7 g/dL and none required a blood transfusion. Of the 11 (11 %) patients 
who reported an adverse event over the study period, three were considered serious and included two deaths and 
one hospitalization; none were causally related to SLD PQ. Four non-serious adverse events were considered defi-
nitely, probably, or possibly related to SLD PQ.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Background
As malaria programmes move towards elimination, 
stopping onward transmission from all detected cases 
becomes increasingly important. The most commonly 
used anti-malarials are artemisinin derivatives, which 
destroy early developing Plasmodium falciparum game-
tocytes (stages I to III) and asexual blood stages of 
human malaria species [1]. However, most symptomatic 
cases present with measurable and transmissible levels 
of mature gametocytes (stages IV and V), as determined 
by Pfs25 RNA-based quantitative nucleic acid sequence-
based amplification (Pfs25 QT-NASBA), which can infect 
mosquitoes, even after completing artemisinin-based 
combination therapy (ACT) [2–4]. The 8-aminoquinoline 
compounds are the only class of drugs effective against 
mature P. falciparum gametocytes. Primaquine (PQ) is 
currently the only licensed anti-malarial in this class of 
drugs.
Since its approval by the FDA in 1952, PQ has been 
used as 14-day anti-relapse treatment against Plasmo-
dium vivax and Plasmodium ovale species [5, 6]. In addi-
tion, in combination with an effective ACT, a single dose 
of PQ can prevent onward transmission of P. falciparum 
[1, 7]. However, PQ can cause haemolysis in people who 
are deficient in glucose-6-phosphate dehydrogenase 
(G6PD) [8]. The extent of an individual’s susceptibility to 
and severity of PQ-induced haemolysis depends on dose 
and duration of PQ exposure, and degree of G6PD defi-
ciency [8–11].
Previously, the World Health Organization (WHO) 
recommended the addition of a single 0.75  mg/kg dose 
of PQ to ACT for the clearance of P. falciparum game-
tocytes. However, low uptake of this recommendation 
and concerns over the potential for haemolytic toxicity 
in G6PD-deficient (G6PDd) individuals prompted the 
issue of a new WHO directive, recommending the use 
of a lower 0.25 mg/kg dose of PQ in areas threatened by 
artemisinin resistance and in settings targeting malaria 
elimination. This 0.25 mg/kg dose should be given to all 
patients with parasitologically-confirmed P. falciparum 
malaria together with ACT, except for pregnant women 
and infants. Prior G6PD testing is not required [12]. 
Despite evidence suggesting that the risks for haemoly-
sis are low at the 0.25  mg/kg PQ dose, it is a common 
concern that PQ, even at low doses, may result in severe 
haemolysis in G6PDd individuals [13]. There remains 
limited data to suggest the safety of this recommenda-
tion and countries have been reluctant to implement the 
policy without more evidence demonstrating that it can 
be safely deployed in their setting.
The use of standardized, prospective pharmacovigi-
lance methods for PQ provides an opportunity to gen-
erate data that can be used to confirm or refute safety 
concerns. To date, pharmacovigilance on PQ is weak 
and relies predominately on passive reporting. In most 
countries in sub-Saharan Africa, passive reporting sys-
tems, which lack an appropriate denominator of persons 
exposed to treatment, are limited or non-existent [14]. 
From a total of 1429 reports (4560 events) submitted to 
the Uppsala Monitoring Center, the WHO’s international 
drug monitoring programme, in which PQ was suspected 
to be a causative or interacting factor for the event, 
89  % were reported from Thailand and only one report 
(3 events) came from Africa [15]. Monitoring the use of 
PQ offers a mechanism to more accurately quantify the 
risk of haemolysis associated with PQ administration, 
especially in patients who are G6PDd. Unlike other anti-
malarial drug regimens where adverse drug reactions 
may be unexpected or poorly defined, requiring weeks 
of follow-up, the objectives for monitoring PQ use are 
straightforward; signs of haemolytic anaemia, the main 
safety concern, can be more specific (i.e., dark urine), 
easily measurable by following haemoglobin concentra-
tion, and attainable within a week of drug administration 
through active surveillance methods.
To support the safe rollout of SLD PQ, the Primaquine 
Roll Out Monitoring Pharmacovigilance Tool (PROMPT) 
was developed in collaboration with the National Malaria 
Control Programme (NMCP) in Swaziland. The objective 
of this study was to assess the feasibility and perceived 
acceptability of using a simple pharmacovigilance tool to 
collect standardized safety data in those prescribed SLD 
PQ therapy for the treatment of P. falciparum malaria.
Methods
This project involved two phases: (1) a tool development 
phase during which the components of PROMPT were 
developed and (2) a pilot phase, when intended end-users 
in Swaziland participated in testing PROMPT alongside 
the introduction of SLD PQ.
Conclusion: Improved pharmacovigilance to monitor and promote the safety of the WHO recommendation is 
needed. The successful application of PROMPT demonstrates its potential as an important tool to rapidly generate 
locally acquired safety data and support pharmacovigilance in resource-limited settings.
Keywords: Elimination, Glucose-6-phosphate dehydrogenase deficiency, G6PD, Malaria, Pharmacovigilance, 
Plasmodium falciparum, Primaquine, Safety
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Tool development
Tools
Through an interactive process, involving a literature 
review and discussions with national and international 
experts, a tool was developed comprising three parts: (1) 
a standardized form (on either a paper or electronic plat-
form) collecting a minimum set of essential data elements 
to support the surveillance of possible adverse events fol-
lowing SLD PQ treatment; (2) a patient information card 
to enhance awareness of known adverse drug reactions 
of SLD PQ use; and (3) a database compiling recorded 
information.
Data collection form
Data collection begins once the prescriber has decided 
to treat confirmed, uncomplicated malaria cases with PQ 
(day 0), in addition to the standard blood schizonticide 
recommended by that particular country. The prescriber 
collects basic socio-demographic data (age, sex, and 
weight), contact information, patient and family history 
data (e.g., severe anaemia, G6PD deficiency, blood trans-
fusions), malaria diagnosis information, and drug dosage 
and frequency data.
For those involved with active surveillance, a blood 
sample is collected to measure haemoglobin or haemato-
crit and to screen for G6PD deficiency. Patients are asked 
to return for a scheduled follow-up visit on or near day 7 
because drug-induced hemolysis and jaundice are clini-
cally detectable within the first 7  days [8]. At this time, 
a repeat haemoglobin or haematocrit measure is taken 
to gauge the degree and speed of decline from the base-
line value prior to starting PQ. Information is also gath-
ered about possible adverse events and serious adverse 
events, defined according to International Conference 
of Harmonization guidelines [16]. The form comprises a 
short list of possible events (e.g., nausea, vomiting, dark 
urine, diarrhoea, etc.) as well as space for recording any 
other signs or symptoms external to the list provided. 
Specifically, data on all new onset or worsening signs 
or symptoms, following PQ treatment (i.e., treatment 
emergent adverse events), regardless of causality, are 
collected. Patients involved with active monitoring who 
miss their day 7 assessments are phoned within a week 
to ask about adverse events. All adverse events reported 
as part of passive or active follow-up record the follow-
ing information: description of the adverse event, date 
of onset, severity grade, actions taken, its relatedness to 
PQ and/or the blood schizonticide used, date resolved, 
outcome of adverse event, and other drugs (including 
traditional medicines) taken along with PQ at the time of 
treatment and in the two-week period prior to the onset 
of the event. Severity grades follow the WHO toxic-
ity grading scale for determining the severity of adverse 
events [17]. In addition, for those presenting with sus-
pected PQ-induced haemolysis, urine colour is recorded 
using a Hillmen colour chart designed to assess the pres-
ence of haemoglobinuria (Additional file  1) [18]. A col-
ourimetric level of 5 or above is considered evidence of 
haemoglobinuria.
Patient information card
At the time of prescribing PQ (day 0), patients are given 
a patient information card with oral and written instruc-
tions on how to identify the signs and symptoms of 
known adverse drug reactions of PQ (e.g., gastrointes-
tinal upset, dark urine, backaches, etc.) and to moni-
tor the colour of their urine (Additional file 2). The card 
also contains instructions of what to do and a telephone 
number to call if adverse drug reactions are experienced. 
Patients are instructed to immediately return to the clinic 
should they experience any adverse reactions following 
PQ treatment.
Database
Data from health facilities are uploaded into a secure 
country-level database. In settings where electronic data 
collection is feasible, the database can assist with man-
aging follow-up visits and remind study participants and 
caregivers of follow-up appointments, including produc-
ing a telephone follow-up call list. Anonymized data from 
end-users can then be fed to a global database where data 
can be combined and analysed.
Sample size considerations
Sample size calculations were based on two scenarios 
for detecting a 25 % or greater within-in person reduc-
tion in haemoglobin after PQ treatment in G6PDd per-
sons using a one-sample paired t-test with a 0.05 level 
of significance (one-sided). A 25  % or greater reduc-
tion was regarded as the minimum clinically important 
threshold that would signify caution for implementing 
the addition of SLD PQ to ACT for the treatment of P. 
falciparum infections. Under the first scenario, in pro-
gramme settings where G6PD screening is available at 
the individual level, seven G6PDd individuals would 
provide 80 % power to detect a 25 % or greater within-
person reduction in haemoglobin, assuming a mean 
haemoglobin of 10  g/dL before treatment, a standard 
deviation of 2  g/dL for the within-person change in 
haemoglobin, and up to 25  % loss to follow-up. In the 
second scenario, in programme settings where G6PD 
screening is unavailable and status is unknown, a pro-
gramme with an estimated 10 % population prevalence 
of G6PD deficiency would, under the same assump-
tions, need to treat a minimum of 70 individuals with 
SLD PQ (Additional file 3).
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Pilot phase
Study area
In response to a request from the Ministry of Health 
(MoH), PROMPT was first piloted in the Lubombo and 
Manzini regions of the Kingdom of Swaziland alongside 
the introduction of SLD PQ. Good Shepherd Mission 
Hospital, a rural, regional referral hospital in Lubombo, 
and Raleigh Fitkin Memorial Hospital, a hospital in 
Manzini run by the Catholic mission and government 
were both purposively selected by the NMCP to repre-
sent facilities with the highest burden of malaria cases. 
Lubombo and Manzini reported a total of 266 and 164 
malaria cases, respectively, this past year (March 2014–
April 2015) [19]. Malaria transmission is highest in the 
lowlands of the Lubombo region and peaks in the rainy 
season between November and May. Plasmodium falci-
parum is the predominant parasite species accounting 
for over 99 % of malaria cases. One-third of Swaziland’s 
population is at risk of infection, with residents in the 
Lubombo region near the eastern borders with Mozam-
bique and South Africa at greatest risk.
Pre‑piloting
Stakeholder engagement and workflow integration
The pilot was tested following discussions with key stake-
holders, including the MoH, an experienced database 
developer, infectious disease specialists with pharma-
covigilance expertise, and local health workers (nurses, 
laboratory technologists, nurse matrons and doctors) 
over 6  months. Consultations with the database devel-
oper allowed us to build a user-friendly, electronic data 
collection tool configured to country capacity. Infectious 
disease and pharmacovigilance specialists offered guid-
ance on how to standardize and define the data elements 
(and minimum reporting criteria) collected. Health 
workers reviewed the steps necessary to use PROMPT 
and increased awareness around its use. Observations 
were made at each facility and discussions were con-
ducted with clinic staff to best integrate PROMPT into 
the existing clinical workflow and capture confirmed 
malaria cases.
Training for the pilot evaluation
Nurses from both facilities received a two-day training 
workshop followed by 7  days of pre-pilot on-site train-
ing. Staff from the NMCP, health facility doctors and 
nurse matrons were also invited to the group training to 
enable additional support to trained health workers dur-
ing study implementation. Half way through study imple-
mentation (August 2014) trained health workers received 
a 1-day refresher training. Both trainings focused on 
illustrating routine study procedures. The health work-
ers were trained in data reporting procedures and 
electronic data collection. Each facility received job aids 
(e.g., flowcharts and figures) to offer cues and direction 
on key procedures. Instruction on identifying the signs 
and symptoms of acute haemolytic anaemia, the main 
adverse effect of SLD PQ use, was also given. Training 
objectives also included opportunities for the study team 
to complete tool procedures in a pre-testing environment 
and to solicit feedback from the team on components of 
PROMPT needing further refinement.
Pilot‑testing PROMPT
Recruitment
All patients over 1  year of age and prescribed standard 
doses of first-line artemether-lumefantrine (AL) for con-
firmed, uncomplicated P. falciparum malaria were eligi-
ble to receive SLD PQ. Patients were not deemed suitable 
for SLD PQ treatment if they had any of the following: 
evidence of severe malaria [20]; history of allergies 
to study drugs; acute anaemia, defined as haemoglo-
bin <8  g/dL; were pregnant by pregnancy test among 
women of childbearing age (15–49 years) or breastfeed-
ing. Patients selected for inclusion also had to agree to 
follow-up phone calls and/or visits and had no intentions 
of leaving Swaziland for a 14-day follow-up period.
Procedures
Prior to SLD PQ administration, G6PD deficiency screen-
ing was performed using the CareStart G6PD deficiency 
screening kit (Access Bio. Inc., New Jersey, USA, LOT 
No. GP13E01; GP13C01) and haemoglobin was meas-
ured using HaemoCue 201+ photometers (HaemoCue, 
Angelholm, Sweden). Patients were then treated with 
the WHO recommended single dose of PQ (0.25  mg/
kg) (Primaquine®, Micro Labs Ltd Hosur, Bangalore, 
India) using 7.5 mg PQ tablets, according to four weight 
bands established following discussions with country 
doctors and senior officials from the NMCP (Table  1). 
Primaquine tablets were analysed by high-performance 
liquid chromatography (U.S. Centers for Disease Con-
trol and Prevention, Atlanta, GA, USA) to measure the 
concentration of active pharmaceutical ingredient (API) 
against a reference standard; tested tablets possessed 
over 95 % API. Patients were given SLD PQ with the first 
dose of AL together with food and then directly observed 
Table 1 Dosage chart for single low-dose primaquine
Weight  
(kg)
Number  
of tablets
Dose  
(mg)
Dose range 
(mg/kg)
10–15 0.5 3.75 0.375–0.25
16–30 1 7.5 0.469–0.25
31–45 1.5 11.25 0.363–0.25
>45 2 15 <0.333
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for 30 min. If a patient vomited within 30 min, treatment 
was re-administered. Those who vomited a second time 
were excluded from further SLD PQ dosing.
At the time of prescribing SLD PQ, trained nurses 
collected data as outlined in the data collection form 
and provided patients with a patient information card. 
Patients were scheduled for follow-up visits on or near 
day 7 and received SMS text message reminders 2 days 
prior to scheduled visits and on day 7. Patients were 
also encouraged to follow-up at unscheduled times 
should they feel unwell. Patients were asked general 
open-ended questions to elicit events and to deter-
mine if they had experienced any problems since being 
treated with SLD PQ. Responses were probed to solicit 
further details on reported events. All adverse and seri-
ous adverse events reported by participants were exam-
ined by hospital physicians and recorded by trained 
nurses. If medically indicated, patients were closely 
monitored and appropriate referrals were made accord-
ing to national protocol. Patients were telephoned 
within a week of missed visits to collect information on 
adverse events. Reporting of adverse events followed 
local ethics and UCSF Institutional Review Board 
guidelines.
Questionnaire data from each visit were entered into 
Samsung T211 Galaxy Tab 3 (7.0) 3G (Samsung, Seoul, 
Korea) tablets running Android OS to enable automated 
data collection in the health facilities (Fig.  1). The tab-
lets were synchronized directly to a secure country-level 
database for real-time review. The data were checked by 
a co-investigator for inconsistencies and corrected by 
contacting the study nurses. The database also served to 
manage follow-up visits and remind subjects and caregiv-
ers of follow-up appointments via automated reminders 
using SMS text messaging. In addition, the database pro-
duced a telephone follow-up call list for nurses, accessi-
ble directly from the tablets, to track and follow-up with 
patients who missed their scheduled visits.
Data analysis plan
Outcome measures and definitions
Tool evaluation—feasibility and perceptions of acceptability
To assess feasibility, the proportion enrolled 
among those eligible and the proportion of patients 
Fig. 1 Screenshot images of data collected using Samsung T211 Galaxy Tab 3 (7.0) 3G tablets
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completing study procedures, looking closely at day 7 
follow-up adherence, were measured. Process meas-
ures (e.g., visit length, provider attitudes about clinic 
burden, satisfaction with counselling sessions with 
patients, etc.) and reactions to and ease or challenges 
of study procedures were collected, using a semi-
structured questionnaire, to investigate perceptions 
related to acceptability among trained nurses. Discus-
sions (one per hospital facility) took about 60  min to 
complete. A moderator collected handwritten or elec-
tronic notes.
Safety assessment of single low‑dose primaquine
To assess the safety of introducing SLD PQ, the haemato-
logic response and occurrence of adverse events in those 
receiving SLD PQ therapy were investigated. Haemoglo-
bin concentrations (defined in g/dL) were expressed as 
the absolute and relative change from baseline values (day 
0). Anaemia was classified according to WHO guidelines 
[21] (6–59 months Hb <11 g/dL; 5–11 years Hb <11.5 g/
dL; 12–14 years Hb <12.0 g/dL; ≥15 years, non-pregnant 
women Hb <12.0 g/dL; pregnant women Hb <11.0 g/dL; 
≥15 years men Hb <13.0 g/dL).
Data analysis
Descriptive statistics were used to present the demo-
graphic characteristics of the study population and their 
baseline clinical and biological characteristics. Data were 
presented in terms of mean and standard deviations or 
median and interquartile range for continuous variables 
and percentages for categorical variables. All patients 
with complete haemoglobin values who returned for fol-
low-up within 10  days after treatment were included in 
assessments of haematological changes. Categorical data 
were compared using the Chi square test or a Fisher’s 
exact test, when applicable. Analyses of reported adverse 
events were based on descriptive summaries of fre-
quency, severity, and relatedness to SLD PQ. Quantita-
tive data were analysed using STATA 13.0 (© StataCorp, 
College Station, TX, USA). Qualitative data from inter-
view notes were summarized after familiarization of the 
data using an iterative approach. Emergent themes from 
the data were identified based on frequency of appear-
ance and summarized.
Ethical considerations
The study was approved by review committees at the 
Swaziland MoH (reference MH/599C/FWA 000 15267) 
and the University of California, San Francisco (IRB no. 
13-11626), and granted non-engaged status by the United 
States Centers for Disease Control and Prevention. Par-
ticipants or a parent or guardian for children less than 
7  years of age gave written, informed consent; children 
between the ages of 7 and 17 years gave assent following 
national guidelines.
Results
Feasibility
Over a 13-month pilot period (March 2014–April 2015), 
166 confirmed, uncomplicated malaria cases from two 
hospital facilities in Lubombo (77) and Manzini (89) 
regions were reported through Swaziland’s Health Man-
agement Information System and Immediate Disease 
Notification System. Of those reported, 112/166 (67.5 %) 
patients were seen by four nurses trained in the use of 
PROMPT and screened for inclusion. Ten patients were 
excluded: one tested positive for pregnancy, seven had 
haemoglobin concentrations less than 8  g/dL, and two 
declined to participate. A total of 102 patients (59 from 
Lubombo and 43 from Manzini) were enrolled and 
administered SLD PQ and 98/102 (96.0.  %) were fol-
lowed up with 93/102 (91.2 %) successfully completing all 
follow-up procedures. This included obtaining a repeat 
haemoglobin measurement and collecting data on all 
adverse events experienced since taking SLD PQ (Fig. 2). 
Four patients (3.9  %) were lost to follow-up with no 
data collected after taking SLD PQ at the health facility. 
Demographic characteristics did not differ significantly 
between those who were lost to follow-up and those who 
were retained, except for foreign nationality. Those lost to 
follow-up were more likely to be of foreign nationality.
Patients were scheduled to return on or near day 7 for 
a follow-up visit; however, the timing of scheduled post-
treatment follow-up visits varied. Patients returned for 
a follow-up visit as early as 4  days post-treatment to as 
late as 23 days post-treatment. Nonetheless, adherence to 
visits on or near day 7 was good, with 66/102 (64.7, 95 % 
CI: 54.6–73.9 %) returning promptly on day 7 and 87/102 
(85.3, 95  % CI: 76.9–91.5  %) returning within 10  days 
(range: 4–10) post-treatment for a follow-up visit.
Perceptions of acceptability
All four trained nurses participated in informal 
feedback discussions to offer initial perceptions of 
PROMPT’s acceptability and to suggest ways to improve 
upon the existing tool. The standardized data collec-
tion form using handheld electronic devices was popu-
lar. Nurses noted several benefits of using an electronic 
data entry system over paper for monitoring the safety 
of SLD PQ. All nurses agreed that this included the 
time saved on data entry and half of nurses felt that 
the electronic devices kept patient records confidential 
and accessible only by trained nurses and staff. There 
was also general agreement amongst the nurses that 
the average staff time required for screening and enrol-
ment (27.5 min; range: 20–45 min), and follow-up visits 
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(12.5  min; range: 10–15  min) per patient was accept-
able. This period of time excludes the time taken for 
retrieving missing or additional information.
These discussions also revealed their views on coun-
selling sessions with patients on G6PD deficiency and 
known adverse drug reactions associated with SLD PQ 
use. All nurses agreed that the patient information cards 
were a useful component of PROMPT that facilitated 
the performance of study procedures and conveyed key 
messages. However, nurses agreed that the language used 
to communicate G6PD deficiency and adverse effects of 
SLD PQ use to patients was challenging to develop. In 
addition, nurses highlighted challenges with the adverse 
event reporting process, including challenges with identi-
fying cases as relevant to report. Nurses more frequently 
reported on events that were either severe or life-threat-
ening in nature or expected signs and symptoms of SLD 
PQ use (i.e., dark-coloured urine, anaemia, jaundice).
The main challenge described when using an electronic 
platform was server connectivity; while nurses were still 
able to enter information and store data while the server 
was offline, data could not be synchronized and uploaded 
to the country-level database. This limited capacity to 
monitor and analyse data in real-time and resulted at 
times in delayed or duplicated SMS text messages being 
sent to patients.
Baseline characteristics of participants enrolled in PROMPT
In our cohort of enrolled P. falciparum malaria patients 
treated with SLD PQ who completed follow-up (n = 93), 
the mean age was 25  years, ranging from 13  months to 
68  years (Table  2). Overall, 17.2  % of participants were 
under 5 years of age. Anaemia was frequent before treat-
ment: 26 patients (28.0, 95  % CI: 19.1–38.2  %) were 
mildly anaemic and 36 (38.7, 95 % CI: 28.8–49.4 %) were 
moderately anaemic. The majority of patients less than 
15 years (n = 32) were anaemic at baseline (93.8, 95 % CI: 
79.2–99.2 %). None of the enrolled patients were G6PDd 
at baseline (95  % upper confidence limit [UCL]: 3.6  %). 
One child screened for inclusion was G6PDd; however, 
the child was excluded and not given SLD PQ based on a 
haemoglobin concentration less than 8 g/dL.
Safety assessment of single low‑dose primaquine
Haemolysis
Out of the 93 patients who successfully completed all 
follow-up procedures, 87 patients returned for at least 
one follow-up haemoglobin visit within 10 days of receiv-
ing SLD PQ with 58 (66.7  %) experiencing declines in 
haemoglobin concentration post-treatment. The mean 
absolute reduction in haemoglobin concentration 
within 10 days, relative to day 0 was 0.6 g/dL (95 % CI: 
−0.9–0.3 g/dL; p = 0.0008) (Table 3). The relative mean 
decrease in haemoglobin was 3.7 % (95 % CI: −6.4–1.0 %; 
p  =  0.007). Few patients (11/87, 12.6  %) dropped 2  g/
dL or more relative to day 0 (range: 2.1–5.9  g/dL). The 
maximum absolute decrease in haemoglobin concentra-
tion was 5.9  g/dL though this individual patient started 
with a high haemoglobin concentration of 20.1 g/dL that 
was likely due to dehydration at baseline. Four patients 
(4.6, 95  % CI: 1.3–11.4  %), all male adults with a start-
ing haemoglobin concentration greater than 13  g/dL, 
experienced fractional drops in haemoglobin of 25 % or 
greater from baseline; the median absolute and relative 
drops in haemoglobin among these four patients were 
4.9 g/dL and 30.5 %, respectively. Two patients (2.3, 95 % 
CI: 0.3–8.1 %) dropped below 8 g/dL; both were moder-
ately anaemic at baseline. No patient who fell below 8 g/
112 uncomplicated malaria paents were 
screened
10 paents were excluded based on inclusion 
and exclusion criteria:
7 Hb<8g/dL
1 Pregnant 
2 Declined to parcipate
102 paents were enrolled and received 
addional SLD PQ treatment
4 paents were lost to follow-up
98 paents were followed up
166 confirmed malaria cases reported to 
HMIS/IDNS reporng systems 
87 paents returned within 10 days post-
treatment for a follow-up visit
5 paents, including 2 deaths did not have a 
follow-up haemoglobin measure taken
93 paents had both a follow-up haemoglobin
measure taken and an adverse event 
assessment
Fig. 2 Cohort profile
Table 2 Baseline characteristics (n = 93)
Data are presented as  % (n/N) or median [IQR]
IQR interquartile range
Characteristic % (n/N) or median (IQR)
Female 46 % (43/93)
Participants from Manzini district 59 % (55/93)
Age (years) 27 [5–38]
Weight (kg) 58 [20–71]
Baseline haemoglobin concentration (g/dL) 11 [10–13]
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dL or experienced falls in haemoglobin of 25 % or greater 
post-treatment was clinically symptomatic with signs of 
anaemia or dark urine (macroscopic haemoglobinuria or 
Hillmen urine score ≥5). None of the patients dropped to 
a level below 7 g/dL (95 % UCL: 4.2 %).
Description of reported adverse events
In general, SLD PQ was well tolerated by patients. Out 
of all the patients who received SLD PQ and returned 
for follow-up, 89 % (87/98) of patients did not report any 
adverse event since receiving treatment. Of the 11 (11 %) 
patients who reported an event, three were considered 
serious using ICH guidelines and included two deaths 
and one hospitalization; none were classified as related to 
SLD PQ (Table 4). In all three serious cases, the under-
lying clinical diagnosis was unclear and reported as a 
multitude of symptoms. One death was attributed to the 
patient’s pre-existing immune-compromised condition. 
This patient, presenting with fever, chills, diarrhoea and 
vomiting, was diagnosed with uncomplicated P. falci-
parum malaria, testing positive by rapid diagnostic test 
(RDT) and microscopy. He was admitted to the hospital 
as a precaution to monitor his diarrhoea. The following 
day he was enrolled and treated with AL plus SLD PQ, 
and panadeine. The diarrhoea continued throughout the 
day. He was confused. Diclofenac was added to his treat-
ment. Two days after symptom onset, the patient died. 
Another patient presenting with complaints of weakness, 
jaundice, and coughing, was prescribed AL based on 
signs and symptoms, despite testing negative for malaria 
by RDT and microscopy. When the patient returned to 
the clinic to pick up his AL treatment (two  days after 
event onset), the patient was incorrectly enrolled into 
the study and treated with AL plus SLD PQ. Despite 
anti-malarial therapy, the patient’s condition contin-
ued to deteriorate. Upon active follow-up by telephone, 
the study nurses learned of the patient’s death. A verbal 
autopsy suggested that the patient’s health had deterio-
rated to the point where the patient was unable to pass 
urine. He died within 10 days of initial presentation. One 
patient, with complaints of diarrhoea, vomiting, head-
ache, and dizziness, was admitted and hospitalized one 
day after treatment with SLD PQ but recovered within 
48 h of onset.
None of the patients vomited in the 30  min follow-
ing drug administration. The most frequently reported 
events in all 11 patients were dark urine (36  %), vomit-
ing (27  %), fever (18  %), and diarrhoea (18  %). Four 
non-serious adverse events were considered definitely, 
probably or possibly related to SLD PQ. Of the non-seri-
ous adverse events, all recovered except for one whose 
outcome remains unknown despite multiple telephone 
attempts at follow-up. This patient, following a diagnosis 
of vivax malaria confirmed by microscopy was referred to 
one of the study facilities and received the recommended 
higher dose of PQ (30  mg). Following treatment, the 
patient reported malaise and worsening of symptoms.
Dissemination and impact
Key findings from the safety assessment were dissemi-
nated and recommendations were made (Fig.  3) to key 
stakeholders during the NMCP’s Malaria Elimination 
Advisory Group General Committee meeting in January 
2016. Results and recommendations on safety, dosing, 
and the management of adverse events were shared to 
prepare for countrywide adoption of the WHO recom-
mendation. Regional trainings launching the new diag-
nosis and treatment guidelines followed. As of December 
2015, SLD PQ has been available at all three levels of 
Swaziland’s health system. This includes both public 
and private clinics, health centres, and referral hospitals, 
making Swaziland the first country in sub-Saharan Africa 
to rollout SLD PQ for malaria elimination.
Discussion
This study is the first to demonstrate the feasibility and 
acceptability of performing active safety monitoring using 
a simple pharmacovigilance tool in those prescribed SLD 
PQ therapy for the treatment of P. falciparum malaria. 
Results suggest that PROMPT achieved its objective and 
successfully yielded standardized safety data on the range 
and frequency of adverse events, including haematologic 
changes, experienced after SLD PQ therapy. The data in 
turn contributed to a limited but growing local evidence 
base and offered the program insight prior to country-
wide adoption of WHO policy. These findings are sup-
ported by the following observations.
Firstly, PROMPT promoted and facilitated the cap-
ture of treatment emergent adverse events after initia-
tion of SLD PQ therapy with a known denominator of 
Table 3 Baseline and follow-up values and changes in hae-
moglobin concentration within  10  days post-treatment 
in participants who received AL + SLD PQ (n = 87)
Primaquine was given on day 0 of treatment, together with dose 1 of 
artemether-lumefantrine. Mean absolute change defined as the haemoglobin 
mean on the day of follow-up minus the haemoglobin mean at day 0. Mean 
relative percentage change between day 0 (t1) and follow-up (t2) defined as 
[(hb(t2)−hb(t1))/hb(t1)] × 100
AL artemether-lumefantrine, Hb haemoglobin, SLD PQ single low-dose 
primaquine, SD standard deviation
Characteristic Mean (SD) (range)
Baseline haemoglobin (g/dL) 11.6 (2.3) [8–20.1]
Follow-up haemoglobin (g/dL) 11.0 (1.8) [7.2–15.8]
Absolute change in haemoglobin (g/dL) −0.6 (1.6) [−5.9–3]
Percent change in haemoglobin (g/dL) −3.7 (12.7) [−31.4–30.9]
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the number of people exposed to the drug (n = 102). Cal-
culating adverse drug reaction frequencies or incidence 
rates to examine risk for particular treatments is limited 
with current systems that rely primarily on passive, spon-
taneous reporting [14]. Importantly, patients with signs 
or symptoms suggestive of PQ-induced haemolysis or 
other serious events were, for the most part, promptly 
identified and monitored within a week of drug admin-
istration. Despite two deaths, unrelated to the intake of 
SLD PQ, and one patient who was lost to follow-up after 
receiving a higher dose of PQ (30 mg) for vivax malaria, 
all P. falciparum patients who presented with an adverse 
event recovered. Moreover, repeat haematologic testing 
ensured that clinically important drops in haemoglobin 
(i.e., fractional drops in haemoglobin ≥25 % from base-
line or haemoglobin concentrations <7  g/dL post-treat-
ment) were detected. No patient’s haemoglobin fell below 
7 g/dL and none required a blood transfusion.
Second, this study showed high adherence (>90  %) to 
visits on or near day 7 and demonstrated the acceptability 
of this approach among trained nurses. The use of simple 
approaches—real-time electronic data collection, SMS text 
reminders, follow-up phone calls, and patient information 
cards—encouraged patients to return to clinics and helped 
ensure the timely reporting of safety data to a central repos-
itory. This is in line with prior research illustrating how sen-
sitization and training of health workers and consumers can 
be strong incentives for reporting and adherence to sched-
uled visits [22]. Furthermore, there is growing evidence on 
the impacts of mobile health (mHealth) interventions on 
health outcomes in low- and middle-income countries [23]. 
Pharmacovigilance and post-marketing surveillance of the 
safety and quality of medicines has been proposed as one 
of six areas within malaria control where the use of text 
messaging technology could improve routine delivery of 
health services in Africa [24]. Some settings may however 
not have the resources to support pharmacovigilance strat-
egies that rely on advanced technologies, active follow-up, 
and the literacy of participants. Alternative strategies that 
are feasible and appropriate using paper forms with less-
intense monitoring and patient information cards format-
ted for illiterate individuals using pictorial methods should 
be adopted.
This study did, however, face challenges that are inher-
ent to establishing pharmacovigilance systems with relia-
ble reporting processes [14]. Underreporting, likely due to 
a lack of understanding as to what constitutes an adverse 
event, appears to have been higher than anticipated. 
Results reveal that patients and providers may have selec-
tively reported adverse events potentially associated with 
SLD PQ and suggestive of haemolysis (e.g., dark urine 
and paleness/jaundice). In addition, there was no baseline 
assessment of symptoms in order to reduce the workload 
for healthcare providers. Thus, while procedures speci-
fied that an abnormality present at baseline should not 
be recorded unless it increased in severity, doing so relied 
on patients recalling exactly when symptoms started 
at least  one week prior. Recall is usually better in the 
short-term [25]; however, certain events may have been 
dismissed, especially those less severe, unexpected or 
Table 4 Detailed summary of adverse events and serious adverse events* as reported after exposure to SLD PQ together 
with AL
Dashes represent missing values
AL artemether-lumefantrine, CBC complete blood count, Hb haemoglobin, N/A not applicable, SLD PQ single low-dose primaquine
a Received anti-malarial treatment despite testing negative for malaria by rapid diagnostic test and microscopy
Sex Age  
(years)
Baseline Hb  
(g/dL)
Follow‑up Hb  
(g/dL)
Adverse event Severity 
grade
Actions  
taken
Outcome
Male 32 14.9 13.2 Dark urine Moderate Urinalysis and CBC Recovered
Male 28 15.7 15.8 Dark urine Moderate None Recovered
Female 63 12.6 9.6 Unwell (worsening post-dose) Moderate None Unknown
Female 18 9.2 – Anaemia, back pain, fever, and 
vomiting after meals
Moderate Prescribed drug Recovered
*Female 31 14.1 12.5 Diarrhoea, vomiting, headache, 
and dizziness
Moderate Hospitalization Recovered
Male 5 9.3 8.0 Dark urine (grade: 8) Severe None Recovered
Female 30 14.9 13.6 Nausea Moderate None Recovered
*Male 60 12.8 – Fever, chills, diarrhoea and vomit-
ing
N/A Prescribed drug Fatal
Male 44 9.8 11.2 Dark urine (grade: 5) Mild None Recovered
*Malea 28 19.5 – Weak, jaundice, coughing N/A Prescribed drug Fatal
Female 3 10.5 11.6 Stomach cramps Mild Unknown Recovered
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thought to be a clinical manifestation of malaria, despite 
having an onset post-SLD PQ administration and which 
should, by definition, have been reported. Methods for 
eliciting information could have also varied and influ-
enced the detection of adverse events. Future research 
should explore factors that influence patterns of reporting 
to better accommodate these challenges.
There are limitations to the study also worth noting. 
Sampling was restricted to two hospital facilities in a low 
transmission African setting in relatively healthy par-
ticipants with haemoglobin concentrations of 8  g/dL or 
greater, and no enrolled patients were G6PDd, which may 
limit the generalizability of our findings. Furthermore, by 
not enrolling any G6PDd individuals, the targeted G6PDd 
sample size was not achieved. This could be due to a low 
prevalence of G6PD deficiency in this malaria-infected 
population or due to a multitude of factors that affect the 
performance of G6PD tests. Recent haemolytic events can 
leave patients with a large proportion of young red blood 
cells in circulation. These cells have high G6PD enzyme 
function and can obscure correct diagnosis and produce 
false normal results. In addition, borderline colourimetric 
results can produce subjective and variable readings [26]. 
For these reasons, confirmatory testing would be required 
to avoid misclassification of results and examine this 
in the future. The qualitative rapid test can only reliably 
identify completely deficient phenotypes.
This study also relied on the views of four trained 
nurses to produce opinions on tool acceptability thus 
restricting the breadth of opinions and experiences cap-
tured. Nonetheless, perceptions did demonstrate promise 
that PROMPT would be well received on a larger scale. 
Additional interviews among end users would allow us to 
capture a broader range of views in the future.
Expanding PROMPT’s use beyond Swaziland presents 
an opportunity to address these limitations and improve 
the systematic collection of safety data where data are 
needed. Data that include G6PDd participants are being 
collected from four additional countries across Asia and 
Africa (Bangladesh, Senegal, Sudan and Tanzania) with 
differing levels of risk associated with PQ therapy. As 
data from these sites increases in size, it will be possible 
Fig. 3 Summary of key findings and recommendations
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to pool individual patient data, directly compare, and 
determine the risks of PQ therapy with ever-greater 
accuracy. These new insights could serve to inform the 
highest safe dose of SLD PQ in G6PDd individuals that is 
critical to defining the therapeutic dose range and guid-
ing appropriate dosing regimens [27].
PROMPT could also extend to support pharmacovigi-
lance activities under diverse contexts and in select pop-
ulations. For example, subjects could be followed up at 
additional time points (e.g., days 14 and 28) to assess out-
comes after PQ treatment of longer duration for P. vivax or 
P. ovale. Women of childbearing age inadvertently exposed 
to PQ in very early, unsuspected pregnancy could also be 
identified at around 3 months and prospectively followed 
at regular intervals (e.g., every 3 months or so until several 
weeks post-natal) to assess pregnancy and birth outcomes. 
Data on the use of PQ in pregnancy remains limited and 
further study on the safety of PQ in pregnancy are needed. 
Finally, these tools could be expanded beyond PQ to other 
drugs for a variety of other diseases.
As access to SLD PQ increases, a larger evidence-base 
to support the safety of the latest WHO recommenda-
tion will be needed. Several countries in the Asia Pacific, 
including Bhutan, Indonesia, Malaysia, Myanmar, Thai-
land, the Philippines, and Vietnam include SLD PQ in 
their P. falciparum treatment guidelines, albeit in differ-
ent doses and schedules. And demand for its use is grow-
ing rapidly in parts of Africa with Botswana, Ethiopia, 
Namibia, South Africa, Swaziland, Zanzibar, and Zim-
babwe who have written SLD PQ into national strategic 
plans or treatment guidelines for falciparum malaria [28]. 
Although evidence suggests that the risk of haemolytic 
toxicity in G6PDd individuals treated with a 0.25 mg/kg 
single dose of PQ for falciparum malaria is low [13], no 
medicine is absolutely free from risk. Obtaining safety 
data on the use of SLD PQ in settings that extend beyond 
small and selected populations that are characteristic of 
randomized controlled clinical trials to reflect real-life 
usage in programmatic settings will help reduce uncer-
tainties that surround the safety of SLD PQ. PROMPT 
holds potential for becoming a practical tool for generat-
ing locally acquired safety data and supporting pharma-
covigilance in resource-limited settings, however, wider 
adoption is needed to further evaluate and refine its use.
Additional files
Additional file 1. Urine colour scale designed to assess the degree of 
haemoglobinuria. Dark-coloured urine with a colourimetric of 5 or above 
was considered evidence of haemoglobinuria [18]. With permission from 
the NEJM.
Additional file 2. Example of a patient information card in English.
Additional file 3. Sample size guide.
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